2024

1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

   Cancers, Vol. 16, Núm. 9

2. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

   Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

3. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

   Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

4. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

   Nature Communications, Vol. 15, Núm. 1

5. COPD: systemic proteomic profiles in frequent and infrequent exacerbators

   ERJ Open Research, Vol. 10, Núm. 2

6. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

   British Journal of Surgery, Vol. 111, Núm. 3

7. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology

8. Dietary carbohydrate quality index and incidence of obesity-related cancers in the “Seguimiento Universidad De Navarra” (SUN) prospective cohort

   European Journal of Nutrition

9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

   Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

10. Exploring current and emerging therapies for porphyrias

    Liver International

11. Hacia la estandarización de la formación de PoCUS en nefrología: el momento es ahora

    Nefrologia, Vol. 44, Núm. 1, pp. 5-9

12. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

    Transplantation, Vol. 108, Núm. 3, pp. 787-801

13. Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

    Cell Death Discovery, Vol. 10, Núm. 1

14. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

15. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes

    Journal of Infectious Diseases, Vol. 229, Núm. 6, pp. 1796-1802

16. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

17. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

18. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

19. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

20. Uric Acid and acute kidney injury in high-risk patients for developing Acute Kidney Injury undergoing cardiac surgery: a prospective multicenter study

    Revista Espanola de Anestesiologia y Reanimacion